Corcept Therapeutics revenue jumps 32% to $256.1M on LIFYORLI launch

Corcept Therapeutics reported Q2 revenue of $256.1 million, up 32% year over year, driven by its Cushing's syndrome franchise and the launch of LIFYORLI, its ovarian cancer therapy.

"The strong performance reflects our commercial execution and the successful introduction of LIFYORLI," the company said in its earnings release.

Net income reached $43.0 million for the quarter. The company raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, up from its prior outlook.

Shares jumped 17.4% after the results, as the LIFYORLI launch added a second revenue stream beyond the company's established Cushing's syndrome business. The ovarian cancer drug generated $47.6 million in its first quarter of availability, representing about 19% of total quarterly revenue.

Corcept's Cushing's franchise, anchored by Korlym (mifepristone), continued to generate the majority of sales. The company did not disclose a segment breakdown beyond the LIFYORLI figure. Korlym, approved for Cushing's syndrome in 2012, has been the primary growth driver for Corcept over the past decade and faces limited competition in the market.

The raised guidance implies second-half acceleration, with the midpoint of $1.15 billion suggesting roughly $894 million in revenue for the remaining two quarters. Corcept did not provide an EPS figure or consensus comparison in its preliminary results.

The results show Corcept's expansion into oncology is gaining traction. LIFYORLI enters a competitive ovarian cancer market that includes PARP inhibitors such as Lynparza from AstraZeneca and Zejula from GSK, as well as standard chemotherapy regimens. The company has not disclosed peak sales estimates for the drug, though the first-quarter contribution of $47.6 million provides an early benchmark.

The guidance raise indicates management expects continued momentum from both the Cushing's franchise and the LIFYORLI launch. Investors will watch the Q2 earnings call for updated peak sales projections for LIFYORLI and pipeline developments, including any updates on Corcept's other oncology candidates in development.

This article is for informational purposes only and does not constitute investment advice.